MTFB.L Share Price (MTFB)

This the last I can see .
Published 10 April, 2018 2:20 pm
Rupert Hargreaves
One ‘secret’ growth stock I’d buy alongside this FTSE 100 growth monster
Motif is a high risk, high reward secret growth stock and to reduce the risk of holding it in your portfolio, I would buy it alongside Shire (LSE: SHP).
This hidden growth stock is gearing up to become the next FTSE 100 (INDEXFTSE:UKX) growth champion.
When my Foolish colleague Kevin Godbold last covered Motif Bio (LSE: MTFB) at the end of last year he concluded that, after a recent fundraising supported by a specialist pharmaceutical lender, the firm’s outlook had improved significantly.
Nearly four months on and it looks to me as if this assessment remains accurate.
About to pay off
Motif raised $20m in debt financing from Hercules Capital, a firm specialising in customised debt financing for companies in life sciences and technology-related markets, at the end of last year. This additional cash has helped the company push forward with the development of its flagship iclaprim treatment.
Iclaprim is designed to fill a gap in the traditional antibiotic market by providing a standard of care not currently available to patients who have other health issues, specifically, kidney problems. The size of the potential market for this treatment is growing as more and more people become exposed to issues that may impact kidney function, such as obesity and diabetes.
2018 and 2019 will be a transformational year as the company seeks to get this treatment approved for sale by the US Food and Drugs Administration. It has already met FDA standards in Phase 3 clinical trials conducted throughout 2017, so management is hopeful that it won’t be long before it can start booking revenue from sales.

However, the firm is facing the prospect of a cash crunch.
Motif is generating no revenue and lost a total of $44.8m last year. With cash and cash equivalents of $22.7m at the end of December 2017 (and $15m of the $20m drawn down from debt financing), the firm has less than six months of cash left before new funding is required.
Indeed, today’s full-year earnings release from the company states: “The Group will be required to raise additional capital within the next year.” Still, with Iclaprim on the verge of being approved by regulators, it looks as if the risk/reward is skewed in investors’ favour.
More predictable outlook
Motif is a high risk, high reward .

I made three buys ( D ) April to May 2017.
Made a little back with a small trade Bursary 2019 .
Total loss around 260%

Wuckfit mine have been removed today ( D )
jam2morrow posted below 22/5/22
I would like to think there will be some form of closure in this tax year. It has been previously posted that these shares can be classed as negligable value for tax purposes.......but I didn't have taxable disposals last year to be able to confirm this.

I see the italian was also a holder .

Motif Bio: Lessons from a failed pharma
Catastrophic pharmaceutical failures can provide interesting entry points to investors who know how to trade them
June 16, 2021
By Michael Taylor
Motif Bio failed to get its novel antibiotic approved in the US leading to the eventual collapse of the company
Investors have voted to reject a reverse takeover that might have rescued the company, but given too much to the existing directors

Got the "This company is now worthles" mesage fom HL today.. I wonder if GL got one as wel!

Same @ISA......we haven't had an RNS so i wonder whats changed. Not a lot of use to me this tax year as i don't have any taxable gains that i can discount against MTFB. Does anybody know if we can use this 'deemed worthless' category in the next tax year/ future tax years ?

Just got the above title email in my inbox, referring to a corporate action, from ii.

Had forgotten all about this disaster!